StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) shareholders

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)

Close on Nov 17, 2026Market cap $257.81KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 1M shares
Institutional holders
0
0 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
823,9099.99%13G (passive)Dec 31, 2025
James Foster287,98724.90%13G (passive)Dec 31, 2022

Top institutional holders

13F holdings as of Mar 31, 2026

HolderShares% of VRAXValueChange% of portfolio
Armistice Capital, LLC35,1526.07%$193.25KNew0.00%
Jump Financial, LLC1,6290.28%$8.96KNew0.00%
Osaic Holdings, Inc.10.00%$4–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202600M0.0%0 / 00 / 30M0M
Q1 202630M6.4%2 / 00 / 40M0M
Q4 202550M0.2%3 / 11 / 20M0M
Q3 202540M0.7%3 / 10 / 10M0M
Q2 202520M0.2%1 / 10 / 30M0M
Q1 202540M0.4%3 / 01 / 60M0M
Q4 202470M0.4%6 / 10 / 40M0M
Q3 202450M1.5%2 / 30 / 40M0M
Q2 202470M0.5%5 / 10 / 10M0M
Q1 202430M0.1%1 / 11 / 20M0M
Q4 202340M0.9%4 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Nigel William McCrackenChief Operating Officer, Director––Mar 20, 2026
Jason DavisChief Financial Officer––Mar 18, 2026
James Alexander Cunliffe FosterChief Executive Officer287,98749.72%Mar 18, 2026
Nelson M. HaightDirector––Mar 31, 2026
Evan Michael NortonDirector––Mar 18, 2026
Iain David MillerDirector––Mar 18, 2026
Clement Monteil–––Oct 21, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
3.17%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-25.6%
From 0M shares
Short volume, 20 days
56.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Virax Biolabs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 216,552 shares on Oct 6, 2026 over the last 90 days.

See a number that looks wrong?